Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

An in Vitro Pilot Study of the Role of Factor IX As an Alternative to Bypassing Agents in the Treatment of Breakthrough Bleeds in Patients with Hemophilia a and Inhibitors Treated with Emicizumab

Maissaa Janbain, Laurie Josset, Christophe Nougier, Cindy A. Leissinger, Radia Ksayer, Yesim Dargaud

Blood (2023) 142 (Supplement 1): 5475.

https://doi.org/10.1182/blood-2023-187217

Published: 2023

Journal Articles

Deciphering Thrombosis Risk in Vexas Syndrome Patients through Thrombin Generation Assay Andthromboelastography

Mael Heiblig, Christophe Nougier, Jamilloux Yvan, Pierre Sujobert, Yesim Dargaud

Blood (2023) 142 (Supplement 1): 1280.

https://doi.org/10.1182/blood-2023-185809

Published: 2023

Journal Articles

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Robert Klamroth, Robert F Sidonio, Jr., Yesim Dargaud, Víctor Jiménez-Yuste, Rolf Ljung, Guy Young, Pratima Chowdary

Blood (2023) 142 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2023-181725

Published: 2023

Journal Articles

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Blood (2023) 142 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2023-181299

Published: 2023

Journal Articles

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Amy L. Dunn, Yesim Dargaud, Yasmina L. Abajas, Manuel Carcao, Giancarlo Castaman, Adam Giermasz, Cédric Hermans, Magdalena D. Lewandowska, Johnny Mahlangu, Shannon L. Meeks, Wolfgang A. Miesbach, Michael Recht, Vanessa Salinas, Tammuella Chrisentery-Singleton, Hongying Wang, Ian S Mitchell, Guy Young

Blood (2022) 140 (Supplement 1): 8485–8488.

https://doi.org/10.1182/blood-2022-157343

Published: 2022

Journal Articles

Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI)

C. Escuriola Ettingshausen, Erik Berntorp, MD PhD, Yesim Dargaud, MD PhD, Zeynep Gutowski, PhD, Claude Negrier, Anna Pavlova, MD PhD, Johannes Oldenburg

Blood (2018) 132 (Supplement 1): 2482.

https://doi.org/10.1182/blood-2018-99-114408

Published: 2018

Journal Articles

Hemostatic Effect of the Combination of Factor VIII Concentrate with Tranexamic Acid (TXA) in the Prophylactic Setting in Severe Hemophilia a

Maissaa Janbain, MD, Nathalie Enjolras, PhD, Jean-Claude Bordet, Radu Bolbos, Cindy A. Leissinger, MD, Yesim Dargaud, MD PhD

Blood (2018) 132 (Supplement 1): 2490.

https://doi.org/10.1182/blood-2018-99-119407

Published: 2018

Journal Articles

Genetic Fusion to Factor XIII B-Subunit Improves the Pharmacokinetic Properties of Factor IX

Sandra Le Quellec, MD, Nathalie Enjolras, PhD, Jean-Claude Bordet, Vladmir Jacqueline, Claude Negrier, MD, Yesim Dargaud, MD PhD

Blood (2017) 130 (Supplement 1): 2339.

https://doi.org/10.1182/blood.V130.Suppl_1.2339.2339

Published: 2017

Journal Articles

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Yesim Dargaud, MD PhD, Anne Lienhart, MD, Nathalie Enjolras, PhD, Claude Negrier, MD

Blood (2017) 130 (Supplement 1): 3675.

https://doi.org/10.1182/blood.V130.Suppl_1.3675.3675

Published: 2017

Journal Articles

Adeno-Associated Virus Mediated Gene Transfer with Hyperfunctional FIX-E410H Variant Improves Mean Factor IX Activity Levels in Hemophilia B Mice

Sandra Le Quellec, MD, Allison P Dane, PhD, Claude Negrier, Yesim Dargaud, MD PhD, Amit C Nathwani, MD PhD, Nathalie Enjolras, PhD

Blood (2017) 130 (Supplement 1): 4610.

https://doi.org/10.1182/blood.V130.Suppl_1.4610.4610

Published: 2017

Journal Articles

Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation

Yesim Dargaud, Jean Yves Scoazec, Simone J. H. Wielders, Christine Trzeciak, Tilman M. Hackeng, Claude Négrier, H. Coenraad Hemker, Theo Lindhout, Elisabetta Castoldi

Blood (2015) 125 (9): 1497–1501.

https://doi.org/10.1182/blood-2014-10-604553

Published: 2015

Journal Articles

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives

Guy Young, Benny Sørensen, Yesim Dargaud, Claude Negrier, Kathleen Brummel-Ziedins, Nigel S. Key

Blood (2013) 121 (11): 1944–1950.

https://doi.org/10.1182/blood-2012-08-378935

Published: 2013

Journal Articles

Recombinant Porcine Factor VIII Corrects Thrombin Generation and Improves Clot Structure In Vitro in Plasma Containing Anti-Factor VIII Inhibitory Antibodies

Claude Negrier, Shannon L. Meeks, MD, Johannes Oldenburg, Uri Martinowitz, Jean-Claude Bordet, Bernd Poetzsch, Raed Al Dieri, Yesim Dargaud, Coen Hemker, Carel Eckmann, Ed Gomperts, Martin Lee

Blood (2011) 118 (21): 2282.

https://doi.org/10.1182/blood.V118.21.2282.2282

Published: 2011

Journal Articles

The Impact of Factor IX Level on Thrombin Generation and Bleeding During Warfarin Anticoagulation

Yesim Dargaud, Maureane Hoffman, MD, PhD, Claude Negrier, MD, Leana Lefrapper, Dougald M. Monroe, III, PhD

Blood (2011) 118 (21): 541.

https://doi.org/10.1182/blood.V118.21.541.541

Published: 2011

Journal Articles

Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery

Yesim Dargaud, Anne Lienhart, Claude Negrier

Blood (2010) 116 (25): 5734–5737.

https://doi.org/10.1182/blood-2010-06-291906

Published: 2010

Journal Articles

Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.

Benny Sørensen, MD, Ph.D., Yesim Dargaud, Gili Kenet, MD, PhD, Jeanne M. Lusher, MD, Andrew Mumford, Steven W. Pipe, MD, Andreas Tiede, MD, PhD

Blood (2009) 114 (22): 4443.

https://doi.org/10.1182/blood.V114.22.4443.4443

Published: 2009

Journal Articles

How can We Predict Efficacy of rFVIIa in Hemophilia Patients with Inhibitors?

Yesim Dargaud, MD, PhD, Jean C Bordet, Chantal Huchon, Claude Negrier, MD

Blood (2009) 114 (22): 3487.

https://doi.org/10.1182/blood.V114.22.3487.3487

Published: 2009

Journal Articles

Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.

Nathalie Enjolras, PhD, Yesim Dargaud, MD, PhD, Jean-Luc Plantier, PhD, Heli Simpson, Florine Guillaume, Claude Negrier, MD

Blood (2009) 114 (22): 4202.

https://doi.org/10.1182/blood.V114.22.4202.4202

Published: 2009

Journal Articles

Inactivation-Resistant Recombinant Factor VIII Exhibits Superior Thrombin Generation Capacity in Comparison to Wild-Type and B Domain-Deleted Factor VIII.

Joshua Russell, Yesim Dargaud, MD, Randal J. Kaufman, PhD, Claude Negrier, MD, PhD, Steven W. Pipe, MD

Blood (2006) 108 (11): 1604.

https://doi.org/10.1182/blood.V108.11.1604.1604

Published: 2006

NARROW

An in Vitro Pilot Study of the Role of Factor IX As an Alternative to Bypassing Agents in the Treatment of Breakthrough Bleeds in Patients with Hemophilia a and Inhibitors Treated with Emicizumab

Deciphering Thrombosis Risk in Vexas Syndrome Patients through Thrombin Generation Assay Andthromboelastography

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI)

Hemostatic Effect of the Combination of Factor VIII Concentrate with Tranexamic Acid (TXA) in the Prophylactic Setting in Severe Hemophilia a

Genetic Fusion to Factor XIII B-Subunit Improves the Pharmacokinetic Properties of Factor IX

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Adeno-Associated Virus Mediated Gene Transfer with Hyperfunctional FIX-E410H Variant Improves Mean Factor IX Activity Levels in Hemophilia B Mice

Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives

Recombinant Porcine Factor VIII Corrects Thrombin Generation and Improves Clot Structure In Vitro in Plasma Containing Anti-Factor VIII Inhibitory Antibodies

The Impact of Factor IX Level on Thrombin Generation and Bleeding During Warfarin Anticoagulation

Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery

Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.

How can We Predict Efficacy of rFVIIa in Hemophilia Patients with Inhibitors?

Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.

Inactivation-Resistant Recombinant Factor VIII Exhibits Superior Thrombin Generation Capacity in Comparison to Wild-Type and B Domain-Deleted Factor VIII.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only